Диагностика и лечение постинсультных когнитивных нарушений

1. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001.
2. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Эпидемиология инсульта в России. Журн. неврол. и психиат. Инсульт. 2003; 8: 4–9.
3. Дамулин И.В. Сосудистая деменция. Неврол. журн. 1999; 4: 4–11.
4. Левин О.С., Дамулин И.В. Диффузные изменения белого вещества и проблема сосудистой деменции. В кн.: Достижения в нейрогериатрии. Под ред. Н.Н.Яхно, И.В.Дамулина. М.: ММА, 1995; с. 189–228.
5. Левин О.С., Усольцева Н.И., Юнищенко Н.А. Постинсультные когнитивные нарушения. Трудн. пациент. 2007; 8: 26–9.
6. Левин О.С. Применение цитиколина в лечении инсульта. Рус. мед. журн. 2008; 26: 1772–7.
7. Левин О.С. Диагностика и лечение деменции в клинической практике. М.: Медпресс-информ, 2009.
8. Скворцова В.И., Бойцова А. Нейропротективная терапия цитиколином в остром периоде церебрального инсульта. Врач. 2007; 12: 25–8.
9. Суслина З.А., Варакин Ю.А., Верещагин Н.В. Сосудистые заболевания головного мозга. М.: Медпресс-информ, 2006.
10. Хендерсон А.С. Деменция. Женева: ВОЗ, 1995.
11. Agnoli A, Fioravanti M, Lechner H. Efficacy of CDPcholine in chronic cerebral vascular diseases (CCV). In: Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine. V.Zappia (Ed.), Elsevier, Amsterdam, 1985; 305–15.
12. Amenta F, Di Tullio MA, Tomassoni D. The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin Exp Hypertens 2002; 24.
13. Cacabelos R, Alvarez XA, Franco A et al. Therapeutic effects of CDPcholine in Alzheimer's disease and multi-infarct dementia. Ann Psychiat 1992; 3: 233–45.
14. Capurso A, Capurso S, Panza F et al. Efficacy of cytidine diphosphate choline in patients affected by chronic cerebrovascular disease. Clin Drug Invest 1996; 12: 26–38.
15. Chandra B. Treatment of multi-infarct dementia with citicholine. J Stroke Cerebrovasc Dis 1992; 2: 232–3.
16. Clark W, Williams BJ, Selzer KA et al. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke 1999; 30: 2592–7.
17. Cohen RA, Browndyke JN, Moser DJ et al. Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes. Cerebrovasc Dis 2003; 16: 199–204.
18. Desmond DW, Moroney JT, Paik MC et al. Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000; 56: 1124–31.
19. Eberhardt R, Dehrr I. Eficacia y tolerancia de CDP-colina en pacientes geriatricos con insuficiencia cerebral senil. Rev Esp Geriatr Gerontol 1989; 24 (Suppl. 1): 73–81.
20. Fioravanti M, Buckley AE, Agnoli A. Citicoline in CCVD patients: Preliminary results of a multicenter study. Cerebral Pathology in Old Age: Neuroradiological and Neurophysiological Correlations, Pavia 1982.
21. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDPcholine) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. The Cochrane Database of Systematic Reviews 2009, Issue 3.
22. Henon H, Durieu I, Guerouaou D et al. Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology 2001; 57: 1216–22.
23. Leys D, Неnon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol 2005; p. 752–9.
24. O'Brien JT. Medial temporal atrophy rather than white matter hyperintensivities predict cognitive decline in stroke survivors. VASCOG, San Antonio, 2007; p. 31.
25. Parnetti L, Mignini F, Tomassoni D et al. Cholinergic precursorsin the treatment of cognitive impairment of vascular origin. J Neurol Sci 2007; 257: 264–9.
26. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with prestroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009; 8: 1006–18.
27. Piccoli F, Battistini N, Carbonin P et al. CDP-choline in the treatment of chronic cerebrovasculopathies. Arch Gerontol Geriatry 1994; 18: 161–8.
28. Purandare N, Burns A, Daly KJ et al. Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia. BMJ 2006; doi:10.1136.
29. Rasquin SM, Verhey FR, van Oostenbrugge RJ et al. Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Neurosurg Psychiat 2004; 75: 1562–7.
30. Rasquin SM, Lodder J, Ponds RW et al. Cognitive functioning after stroke: a one-year follow-up study. Dement Geriatr Cogn Disord 2004; 18: 138–44.
31. Renshaw PF, Babb SM, Yurgelun-Todd DA et al. Chronic citicholine (CDP-choline administration alters brain phospholipid metabolites and improves cognitive performance in healthy, older adults. 37th ACNP Annual Meeting: Puerto Rico, 1998.
32. Roman GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–60.
33. Sachdev PS, Brodaty Н, Valenzuela MJ et al. The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology 2004; 62: 912–9.
34. Schneider JA, Wilson RS, Bienias JL et al. Cerebral infarcts and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004; 62: 1148–55.
35. Secades J, Lorenzo J. Citicoline. Pharmacol Clin Rev 2006; 27 (Suppl. B): 1–56
36. Snaphaan L, De Leeuv E. Poststroke memory function in nondemented patients. Stroke 2007; 38: 192–203.
37. Tanaka Y, Minematsu K, Hirano T et al. Effects of CDP-choline on dynamic changes in LCBF and cognitive function in demented subjects-PET study. Rinsho Shinkeigaku 1994; 34: 877–81.